CSD, BBB and MMP-9 elevations: Animal experiments versus clinical phenomena in migraine

Expert Review of Neurotherapeutics

Volumn 9, Issue 11, 2009, Pages 1595-1614

  Gupta, Vinod Kumar ^a  

^a Gupta Medical Center S 407   (India)

Author keywords

BBB; Botulinum toxin; Cortical spreading depression; Extracellular matrix; Matrix metalloproteinase; Migraine; Patent foramen ovale; White matter lesion

Indexed keywords

DEXAMETHASONE; GELATINASE B; GLUCOCORTICOID; GLYCERYL TRINITRATE; ION CHANNEL; PREDNISONE;

BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN PERFUSION; CELL JUNCTION; DRUG BLOOD LEVEL; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HEADACHE; HUMAN; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NAUSEA AND VOMITING; NEUROGENIC INFLAMMATION; NEUROPHARMACOLOGY; NEUROPHYSIOLOGY; NONHUMAN; REVIEW; SPREADING CORTICAL DEPRESSION; TIGHT JUNCTION;

ANIMALS; BLOOD-BRAIN BARRIER; CORTICAL SPREADING DEPRESSION; DISEASE MODELS, ANIMAL; HUMANS; MATRIX METALLOPROTEINASE 9; MIGRAINE DISORDERS;

EID: 70849105632     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.103     Document Type: Review

References (228)

1. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol. 33, 48-56 (1993).
2. Haerter K, Ayata C, Moskowitz MA. Cortical spreading depression: a model for understanding migraine biology and future drug targets. Headache Curr. 2(5), 97-103 (2005).
3. Takano T, Tian G-F, Peng W et al. Cortical spreading depression causes and coincides with tissue hypoxia. Nat. Neurosci. 10(6), 754-762 (2007).
4. Iadecola C. From CSD to headache: a long and winding road. Nat. Med. 8, 110-112 (2002).
5. Gorji A. Spreading depression: a review of the clinical relevance. Brain Res. Rev. 38, 33-60 (2001).
6. Somjen GG. Mechanisms of spreading depression and hypoxic spreading-depression like depolarization. Physiol. Rev. 81(3), 1065-1096 (2001).
7. Bigal ME, Lipton RB. Concepts and mechanisms of migraine chronification. Headache 48, 7-15 (2008). • Conceptualizes migraine as a progressive rather than simply an episodic disorder.
8. Leão AAP. Spreading depression of activity in cerebral cortex. J. Neurophysiol. 7, 359-390 (1944).
9. Lashley KS. Patterns of cerebral integration indicated by the scotomas of migraine. Arch. Neurol. Psychiatry 46, 259-264 (1941).
10. Blau JN. Migraine: theories of pathogenesis. Lancet 339, 1202-1207 (1992).
11. Gloor P. Migraine and regional cerebral blood flow. Trends Neurosci. 21, 9 (1986).
12. Pearce JMS. Is migraine explained by Leão's spreading depression? Lancet 2(8458), 763-766 (1985).
13. Gupta VK. Adaptive Mechanisms in Migraine - A Conceptual Synthesis in Evolution. Breaking the Migraine Code. Nova Science, NY, USA (2009).
14. Olsen TS. Is it really true that spreading depression is the cause of the migraine aura? News Headache 4(2), 7 (1994).
15. Maranhão-Filho P, Vincent M. Professor Aristides Leão. Much more than spreading depression. Headache 49, 110-116 (2009).
16. Thompson CS, Hakim AM. Cortical spreading depression modifies components of the inflammatory cascade. Mol. Neurobiol. 32, 51-58 (2005).
17. Yanamoto H, Miyamoto S, Tohnai N et al. Induced spreading depression activates persistent neurogenesis in the subventricular zone, generating cells with markers for divided and early committed neurons in the caudate putamen and cortex. Stroke 36, 1544-1550 (2005).
18. Oton T, Greenberg JH, Welsh FA. Cortical spreading depression causes a long-lasting decrease in cerebral blood flow and induces tolerance to permanent focal ischemia in rat brain. J. Cereb. Blood. Flow. Metab. 23, 43-50 (2003).
19. Woods R, Iacoboni M, Mazziotta JC. Bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N. Eng. J. Med. 331, 1689-1692 (1994).
20. Hadjikhani N, Sanchez del Rio M, Wu O. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc. Natl Acad. Sci. USA 98, 4687-4692 (2001).
21. Bowyer SM, Aurora KS, Moran JE, Tepley N, Welch KM. Magnetoencephalographic fields from patients with spontaneous and induced migraine aura. Ann. Neurol. 50, 582-587 (2001).
22. Gorji A, Scheller D, Straub H et al. Spreading depression in human neocortical slices. Brain Res. 906, 74-83 (2001).
23. Mayevsky A, Doron A, Manor T et al. Cortical spreading depression recorded from human brain using a multiparametric monitoring system. Brain Res. 740, 268-274 (1996).
24. Strong AJ, Fabricus M, Boutelle MG et al. Spreading and synchronous depressions of cortical activity in acutely injured human brain. Stroke 33, 2738-2743 (2002).
25. Fabricius M, Fuhr S, Bhatia R et al. Cortical spreading depression and peri-infarct depolarization in acutely injured human cerebral cortex. Brain 129, 778-790 (2006). •• Presents conclusive evidence for occurrence of cortical spreading depression (CSD) and peri-infarct depolarization in acutely injured human brain.
26. Dreier JP, Major S, Manning A et al. Cortical spreading ischaemia is a novel process involved in ischaemic damage in patients with aneurysmal subarachnoid haemorrhage. Brain 132(Pt 7), 1866-1881 (2009).
27. Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain 117, 199-210 (1994).
28. Olesen J, Friberg L, Olsen TS et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann. Neurol. 28, 791-798 (1990).
29. Lauritzen M, Olesen J. Regional cerebral blood flow during migraine attacks by Xenon-133 inhalation and emission tomography. Brain 107, 447-461 (1984).
30. Gelmers HJ. Common migraine attacks preceded by focal hyperemia and parietal oligemia in the rCBF pattern. Cephalalgia 2, 29-32 (1982).
31. Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann. Neurol. 9, 344-352 (1981).
32. Olsen TS, Friberg L, Lassen NA. Ischemia may be the primary cause of the neurological deficits in classic migraine. Arch. Neurol. 44, 156-161 (1987).
33. Olsen TS, Lassen NA. Blood flow and vascular reactivity during attacks of classic migraine - limitations of the Xe-133 intraarterial technique. Headache 29, 15-20 (1989).
34. Olsen TS. Spreading oligemia in the migraine aura - most likely an artifact due to scattered radiation. Cephalalgia 13, 86-88 (1993).
35. Kobari M, Meyer JS, Ichijo M, Imai A, Oravez WT. Hyperperfusion of cerebral cortex, thalamus and basal ganglia during spontaneously occurring migraine headaches. Headache 29, 282-289 (1989).
36. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat. Med. 8, 136-142 (2002).
37. Maxner CE, Moeller JJ. Visual disturbances and migraine. Curr. Neurol. Neurosci. Rep. 5, 376-381 (2005).
38. Chronicle EP, Mulleners WM. Visual system dysfunction in migraine: a review of clinical and psychophysical findings. Cephalalgia 16, 525-535 (1996).
39. Hupp SL, Kline LB, Corbett JJ. Visual disturbances of migraine. Surv. Ophthalmol. 33, 221-236 (1989).
40. Campbell JK. Manifestations of migraine. Neurol. Clin. 8, 841-855 (1990).
41. Martins-Ferreira H. Spreading depression in the chick retina. In: The brain and behaviour of the fowl. Okawa T (Ed.). Japanese Societies Press, Tokyo, Japan 317-333 (1983).
42. Bures J, Buresova O, Krivanek J. The Mechanism and Applications of Leão's Spreading Depression of Electroencephalographic Activity. Academia, Prague, Czech Republic (1974).
43. Vanopdenbosch L, Horroelen L. Leão's cortical spreading depression and the somatosensory homunculus: a contradiction? Headache 38, 322-323 (1998).
44. Gotoh F, Komatsumoto S, Araki N, Gomi S. Noradrenergic nervous activity in migraine. Arch. Neurol. 41, 951-955 (1984).
45. Havanka-Kannianen H, Tolonen U, Myllyla VV. Autonomic dysfunction in adult migraineurs. Headache 26, 425-430 (1986).
46. Shechter A, Stewart WF, Silberstein SD, Lipton RB. Migraine and autonomic nervous system function. A population-based, case-control study. Neurology 58, 422-427 (2002).
47. Moskowitz MA, Bolay H, Dalkara T. Deciphering migraine mechanisms: clues from familial hemiplegic migraine genotypes. Ann. Neurol. 55(2), 276-280 (2004).
48. Ferrari MD. Migraine genetics: a fascinating journey towards improved migraine therapy. Headache 48(5), 697-700 (2008).
49. Gursoy-Ozdemir Y, Qiu J, Matsuoka N et al. Cortical spreading depression activates and upregulates MMP-9. J. Clin. Invest. 113, 1447-1455 (2004). • Provides evidence for CSD-induced alteration of the BBB through activation of brain MMPs in experimental animals.
50. Nedergaard M, Hansen AJ. Spreading depression is not associated with neuronal injury in the normal brain. Brain Res. 24, 395-398 (1988).
51. Lian XY, Stringer JL. Energy failure in astrocytes increases the vulnerability of neurons to spreading depression. Eur. J. Neurosci. 19, 2446-2454 (2004).
52. Gaist D, Pedersen L, Madsen C et al. Long-term effects of migraine on cognitive function. A population-based study of Danish twins. Neurology 64, 600-607 (2005).
53. Friedman AP. Headache. In: Clinical Neurology. Baker AB, Joynt RJ (Eds). Harper & Row, PA, USA 1-50 (1985).
54. Koroleva VI, Bures J. Rats do not experience cortical or hippocampal spreading depression as aversive. Neurosci. Lett. 149, 153-156 (1993).
55. Huston JP, Jan Bures J. Drinking and eating elicited by cortical spreading depression. Science 169, 702-704 (1970).
56. Carew TJ, Crow TJ, Petrinovich LF. Lack of coincidence between neural and behavioral manifestations of cortical spreading depression. Science 169, 1339-1342 (1970).
57. Monda M, Pittman QJ. Cortical spreading depression blocks prostaglandin E1 and endotoxin fever in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 264, R456-R459 (1993).
58. Read SJ, Smith MI, Benham CD, Hunter AJ, Parsons AA. Furosemide inhibits regenerative cortical spreading depression in anesthetized cats. Cephalalgia 17, 826-832 (1997).
59. de Almeida RF, Leão IAT, Gomes JBL, da Silva Jr AA, Teixeira AL. Migraine with persistent visual aura: response to furosemide. Clinics (Sao Paulo) 64(4), 375-376 (2009).
60. Rozen TD. Treatment of a prolonged migrainous aura with intravenous furosemide. Neurology 55(5), 732-733 (2000).
61. Kaube H, Goadsby PJ. Anti-migraine compounds fail to modulate the propagation of cortical spreading depression in the cat. Eur. Neurol. 34, 30-35 (1994).
62. Alemdar M, Akman Ö, Selekler HM, Komsuoglu SS, Ates N. Does metoprolol inhibit the cortical spreading depression? Acute effects of systematic metropol on CSD in rats. Cephalalgia 27, 1010-1013 (2007).
63. Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA. Suppression of cortical spreading depression in migraine prophylaxis. Ann. Neurol. 59, 652-661 (2006). • Offers conclusive evidence for dose- and time-dependent suppression of CSD by migraine prophylactic agents in experimental animals.
64. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N. Engl. J. Med. 346, 257-270 (2002).
65. Lampl C, Bonelli S, Ransmayr G. Efficacy of topiramate in migraine aura prophylaxis: preliminary results of 12 patients. Headache 44, 174-176 (2004).
66. Piper RD, Edvinsson L, Ekman R, Lambert GA. Cortical spreading depression does not result in the release of calcitonin-gene related peptide into the external jugular vein of the cat: relevance to human migraine. Cephalalgia 13, 180-183 (1993).
67. Guedes RC, Cavalthreiro EA. Blockade of spreading depression in chronic epileptic rats. Epilepsy Res. 27, 133-136 (1997).
68. Sacco RL, DeRossa JT, Haley EC Jr et al. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. JAMA 285, 1719-1728 (2001).
69. Lees KR, Asplund K, Carolei A et al. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomized controlled trial. GAIN International Investigators 10. Lancet 355, 1949-1954 (2000).
70. Heiss WD, Thiel A, Grond M, Graf R. Which targets are relevant for therapy of acute ischemic stroke? Stroke 30, 1486-1489 (1999).
71. Moskowitz MA, Nozaki K, Kraig RP. Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. J. Neurosci. 13, 1167-1177 (1993).
72. Ingvardsen BK, Laursen H, Olsen UB, Hansen AJ. Possible mechanism of c-fos expression in trigeminal nucleus caudalis following cortical spreading depression. Pain 72, 407-415 (1997).
73. Ebersberger A, Schaible H-G, Averbeck B, Richter F. Is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache? Ann. Neurol. 49, 7-13 (2001).
74. Lambert GA, Michalicek J, Storer RJ, Zagami AS. Effect of cortical spreading depression on activity of trigeminovascular sensory neurons. Cephalalgia 19, 631-638 (1999).
75. Bartsch T. Migraine and the neck: new insights from basic data. Curr. Pain Headache Rep. 9, 191-196 (2005).
76. Campbell JK. Facial pain due to migraine and cluster headache. Semin. Neurol. 8, 324 (1988).
77. Bannister LH, Berry MM, Collins P, Dyson M, Dussek JE, Ferguson MWJ. Gray's Anatomy (38th Edition). Churchill Livingstone, NY, USA 1232 (1995).
78. Bohotin V, Fumal A, Vandenheede M, Bohotin C, Schoenen J. Excitability of visual V1-V2 and motor cortices to single transcranial magnetic stimuli in migraine: a reappraisal using a figure-of-eight coil. Cephalalgia 23, 264-270 (2003).
79. Chronicle EP, Mulleners WM, Palmer JE, Vredeveld JW, Koehler PJ. Transcranial magnetic stimulation confirms visual cortical hyperexcitability in migraine, but response to valproate is variable. Neurology 54(Suppl. 3), (2000) (Abstract A128).
80. Schatzberg AF, Nemeroff CB. Essentials of Clinical Psychopharmacology (2nd Edition). American Psychiatric Publishers, DC, USA 12-13 (2006).
81. Bodner RA, Lynch T, Lewis L, Kahn D. Serotonin syndrome. Neurology 45, 219-223 (1995).
82. Shulman BH. Psychiatric aspects of headache. Med. Clin. North Am. 75, 707-715 (1991).
83. Jarcho S. General Grant's headache. Bull. NY Acad. Med. 43, 1224-1226 (1967).
84. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann. Neurol. 47, 614-624 (2000).
85. Dahlöf C. Cutaneous allodynia and migraine: another view. Curr. Pain Headache Rep. 10(3), 231-238 (2006).
86. Lovati C, D'Amico, Bertora P et al. Acute and interictal allodynia in patients with different headache forms: an Italian pilot study. Headache 48(2), 272-277 (2008).
87. Young WB, Gangal KS, Aponte RJ, Kaiser RS. Migraine with unilateral motor symptoms (MUMS): a case control study. J. Neurol. Neurosurg. Psychiatry 78, 600-604 (2006).
88. Lovati C, D'Amico D, Bertora P. Allodynia in migraine: frequent random association or unavoidable consequence? Exp. Rev. Neurother. 9(3), 395-408 (2009).
89. Silberstein SD, Young WB. Migraine aura and prodrome. Semin. Neurol. 15, 175-182 (1995).
90. Cruickshank JM, Neil-Dwyer G. β-blocker brain concentrations in man. Eur. J. Clin. Pharm. 28(Suppl.), 21-23 (1985). •• Provides conclusive evidence for poor penetration of atenolol into the cerebrospinal fluid/brain.
91. Emilien G, Maloteaux JM. Current therapeutic uses and potential of β-adrenoceptor agonists and antagonists. Eur. J. Clin. Pharmacol. 53, 389-404 (1998).
92. Stensrud P, Sjaastad O. Comparative trial of tenormin (atenolol) and inderal (propranolol) in migraine. Upsala J. Med. Sci. Suppl. 31, 37-40 (1980). •• Provides conclusive evidence for the migraine preventive efficacy of atenolol, a hydrophilic agent that does not cross the BBB.
93. Gupta VK. Pharmacotherapeutics of migraine and the blood-brain barrier: serendipity, empiricism, hope, and hype. Med. Gen. Med. 8(2), 89 (2006).
94. Schoonman GG, van der Grond J, Kortmann C, van der Geest RJ, Terwindt GM, Ferrari MD. Migraine headache is not associated with cerebral or meningeal vasodilatation - a 3T magnetic resonance angiography study. Brain 131, 2192-2200 (2008).
95. de Tommaso M, Libro G, Guido M et al. Nitroglycerin induces migraine headache and central sensitization phenomena in patients with migraine without aura: a study of laser evoked potentials. Neurosci. Lett. 363, 272-275 (2004). •• Offers important evidence for the dissociation between headache-provoking and aura-provoking effects of nitroglycerin.
96. Read SJ, Smith MI, Hunter AJ, Parsons AA. The dynamics of nitric oxide release measured directly and in real time following repeated waves of cortical spreading depression in the anaesthetized cats. Neurosci. Lett. 232, 127-130 (1997).
97. Obrenovitch TP, Urenjak J, Wang M. Nitric oxide formation during cortical spreading depression is critical for rapid subsequent recovery of ionic homeostasis. J. Cereb. Blood. Flow. Metab. 22, 680-688 (2002).
98. Colonna DM, Meng W, Deal DD, Gowda M, Busija DW. Neuronal NO promotes cerebral cortical hyperemia during cortical spreading depression in rabbits. Am. J. Physiol. 272(3 Pt 2), H1315-H1322 (1997).
99. Ulmer HJ, de Lima VM, Hanke W. Effects of nitric oxide on the retinal spreading depression. Brain Res. 691, 239-242 (1995).
100. Afridi SK, Kaube H, Goadsby PJ. Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain 110, 675-680 (2004).
101. Afridi S, Kaube H, Goadsby PJ. Occipital activation in glyceryl trinitrate induced migraine with visual aura. J. Neurol. Neurosurg. Psychiatry 76, 1158-1160, (2005).
102. Bonuso S, Marano E, Stasio ED, Sorge F, Barbieri F, Ullucci E. Source of pain and primitive dysfunction in migraine: an identical site? J. Neurol. Neurosurg. Psychiatry 52, 1351-1354 (1989).
103. McArthur JC, Marek K, Pestronk A, McArthur J, Peroutka SJ. Nifedipine in the prophylaxis of classic migraine. Neurology 39, 284-285 (1989).
104. Diener H-C, Scholz E, Dichgans J et al. Central effects of drugs used in migraine prophylaxis evaluated by visual evoked potentials. Ann. Neurol. 25, 125-130 (1989).
105. Dahlem MA, Chronicle EP. A computational perspective on migraine aura. Prog. Neurobiol. 74, 351-361 (2004).
106. Fuller GN, Gale MV. Migraine aura as artistic inspiration. BMJ 297, 1670-1672 (1988).
107. Van Der Hel WS, Van Den Bergh WM, Nicolay K, Tulleken KAF, Dijkhuizen RM. Suppression of cortical spreading depressions after magnesium treatment in the rat. Neuroreport 9, 2179-2182 (1998).
108. Welch KMA, D'Andrea G, Teply N, Barkley G, Ramadan NM. The concept of migraine as a state of central neuronal hyperexcitability. Neurol. Clin. 8, 817-828 (1990).
109. Durlach J, Pagès N, Bac P, Bara M. Guiet-Bara A. Headache due to photosensitive magnesium depletion. Magnes. Res. 18, 109-122 (2005).
110. Frank LR, Olson CM, Shuler KB, Gharib SF. Intravenous magnesium for acute benign headache in the emergency department: a randomized double-blind placebo-controlled trial. Can. J. Emerg. Med. 6, 327-332 (2004). •• Provides important negative evidence for use of magnesium supplementation for migraine prophylaxis.
111. Wang F, Van Den Eeden SK, Ackerson LM, Salk SE, Reince RH, Elin RJ. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache 43, 601-610 (2003).
112. Ko SH, Lim HR, Kim DC, Han, YJ, Choe, H, Song HS. Magnesium sulphate does not reduce postoperative analgesic requirements. Anesthesiology 95, 640-646 (2001). •• Provides important evidence that exogenous magnesium does not freely cross the BBB.
113. Esen F, Erdem T, Aktan D et al. Effect of magnesium sulfate administration on blood-brain barrier in a rat model of intraperitoneal sepsis: a randomized controlled experimental study. Crit. Care 9, R18-R23 (2005).
114. Kaya M, Gulturk S, Elmas I et al. The effects of magnesium sulfate on blood-brain barrier disruption caused by intracarotid injection of hyperosmolar mannitol in rats. Life Sci. 76, 201-212 (2004).
115. Esen F, Erdem T, Aktan D et al. Effects of magnesium administration on brain edema and blood-brain barrier breakdown after experimental traumatic brain injury in rats. J. Neurosurg. Anesthesiol. 15, 119-125 (2003).
116. Kaya M, Küçük M, Kalayci RB et al. Magnesium sulfate attenuates increased blood-brain barrier permeability during insulin-induced hypoglycemia in rats. Can. J. Physiol. Pharmacol. 79, 793-798 (2001).
117. Altura BT, Altura BM. The role of magnesium in etiology of strokes and cerebrovasospasm. Magnesium 1, 277-291 (1982).
118. Durlach J. Neurological manifestations of magnesium imbalance. Handbook Clin. Neurol. 28, 545-579 (1976).
119. Jain AL, Sethi NC, Babbar PK. A clinical electroencephalographic and trace element study with special reference to zinc, copper, and magnesium in serum and cerebrospinal fluid (CSF) in cases of migraine. J. Neurol. Suppl. 232, 161 (1985).
120. Wong ET, Rude RK, Singer FR, Shaw ST. A high prevalence of hypomagnesemia and hypermagnesemia in hospitalized patients. Am. J. Clin. Path. 79, 348-352 (1983).
121. Steiner TJ, Findley LJ, Yuen AWC. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 17, 109-112 (1997).
122. Silberstein SD, Neto W, Schmitt J, Jacobs D. For the MIGR-001 study group. Topiramate in migraine prevention. Arch. Neurol. 61, 490-495 (2004).
123. Láinez MJA, Pascual J, Pascual AM, Santonja JM, Ponz A, Salvador A. Topiramate in the prophylactic treatment of cluster headache. Headache 43, 784-789 (2003).
124. De Simone R, Marano E, Di Stasio E, Bonuso S, Fiorillo C, Bonavita V. Acetazolamide efficacy and tolerability in migraine with aura: a pilot study. Headache 45, 385-386 (2005).
125. Spacey SD, Hildebrand ME, Materek LA, Bird TD, Snutch TP. Functional implications of a novel EA2 mutation in the P/Q-type calcium channel. Ann. Neurol. 56, 213-220 (2004).
126. Murphy VA, Johanson CE. Acidosis, acetazolamide, and amiloride: effects on 22 Na transfer across the blood-brain and blood-CSF barriers. J. Neurochem. 52, 1058-1063 (1989).
127. Ptácek LJ. Channelopathies: ion channel disorders of muscle as a paradigm for paroxysmal disorders of the nervous system. Neuromuscul. Disord. 7, 250-255 (1997).
128. Hess EJ. Migraines in mice? Cell 87, 1149-1151 (1996).
129. Bannwarth B, Schaeverbeke T, Péhourcq F, Vernhes JP, D'Yvoire MB, Dehais J. Prednisolone concentrations in cerebrospinal fluid after oral prednisolone. Preliminary data. Rev. Rheum. Engl. Ed. 64, 301-304 (1997).
130. Miettinen S, Fusco FR, Yrjänheikki J et al. Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-daspartic acid-receptors and phospholipase A2. Proc. Natl Acad. Sci. USA Neurobiology 94, 6500-6505 (1997).
131. Rozen TD. Migraine headache: immunosuppressant therapy. Curr. Treat. Opt. Neurol. 4, 395-401 (2007).
132. Prakash S, Brahmbhatt KJ, Chawda NT, Tandon N. Hemicrania continua responsive to intravenous methylprednisolone. Headache 49, 604-607 (2009).
133. Wolkowitz OM, Papadopoulos NM, Costello R et al. Prednisone effects on blood-brain barrier permeability and CNS IgG synthesis in healthy humans. Psychoneuroendocrinology 15, 155-158, (1990).
134. Kim G-M, Jin K-S, Chung C-S. Differential effects of corticosteroids on the expression of cyclooxygenase-2, tumour necrosis factor-α and matrix metalloproteinase-9 in an animal model of migraine. Cephalalgia 28, 1179-1187 (2008).
135. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. 2nd edition. Cephalalgia 24 (Suppl. 1), 9-160 (2004).
136. Welch KMA. Migraine. A biobehavioral disorder. Arch. Neurol. 44, 323-327 (1987).
137. Gupta VK. A clinical review of the adaptive potential of vasopressin in migraine. Cephalalgia 17, 561-569 (1997).
138. Valiquette G. The neurohypophysis. Neurol. Clin. 5, 291-331 (1987).
139. Guedes RC, Frade SF. Effect of ethanol on cortical spreading depression. Braz. J. Med. Biol. Res. 26, 1241-1244 (1993).
140. Welch KMA, D'Andrea G, Tepley N, Barkley G, Ramadan NM. The concept of migraine as a state of central neuronal hyperexcitability. Neurol. Clin. 8(4), 817-828 (1990).
141. Zhang ET, Hansen AJ, Wieloch T, Lauritzen M. Influence of MK-801 on brain extracellular calcium and potassium activities in severe hypoglycemia. J. Cereb. Blood Flow Metab. 10(1) 136-139 (1990).
142. Dzwonek J, Rylski M, Kaczmarek L. Matrix metalloproteinases and their endogenous inhibitors in neuronal physiology of the adult brain. FEBS Lett. 567, 129-135 (2004).
143. Chandler S, Miller KM, Clements JM et al. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J. Neuroimmunol. 72, 155-161 (1997).
144. Harik SI, Kalaria RN. The blood-brain barrier: a selective overview. In: Cerebrovascular Diseases. Ginsberg MD and Dietrich WD (Eds). Raven, NY, USA 407-410 (1989).
145. Yong VW, Power C, Forsyth PA et al. Metalloproteinases in biology and pathology of the nervous system. Nat. Rev. Neurosci. 2, 502-511 (2001).
146. Yong VW, Krekoski CA, Forsyth PA et al. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci. 21, 75-80 (1998).
147. Oh LYS, Larsen PH, Krekoski CA, Edwards DR, Donovan F, Werb Z, Yong VW. Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes. J. Neurosci. 19, 8464-8475 (1999).
148. Gottschall PE, Deb S. Regulation of matrix metalloproteinase expression in astrocytes, microgila and neurons. Neuroimmunomodulation 3, 69-75 (1996).
149. Reynolds MA, Kirchick HJ, Dahlen JR et al. Early biomarkers of stroke. Clin. Chem. 49, 1733-1739 (2003).
150. Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia 39, 279-291 (2002).
151. Asahi M, Wang X, Mori T et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J. Neurosci. 21, 7724-7732 (2001).
152. Rosenberg GA, Cunnigham LA, Wallace J et al. Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res. 893, 104-112 (2001).
153. Imamura K, Takeshima T, Fusayasu E, Nakashima K. Increased plasma matrix metalloproteinase-9 levels in migraineurs. Headache 48, 135-139 (2007).
154. Leira R, Sobrino T, Rodríguez-Yáñez M, Blanco M, Arias S, Castillo J. MMP-9 immunoreactivity in acute migraine. Headache 47, 698-702 (2007).
155. Perini F, D'Andrea G, Galloni E et al. Plasma cytokine levels in migraineurs and controls. Headache 45, 926-931 (2005).
156. Ishizaki K, Takeshima T, Fukuhara Y et al. Increased plasma transforming growth factor-β 1 in migraine. Headache 45, 1224-1228 (2005).
157. Kawasaki Y, Xu Z-Z, Wang X et al. Distinct role of matrix metalloproteinases in the early- and late-phase development of neuropathic pain. Nat. Med. 14, 331-336 (2008).
158. Nagase H, Woessner JF. Matrix metalloproteinases: a minireview. J. Biol. Chem. 274, 21491-21494 (1999).
159. Zhao B-Q, Wang S, Kim H-Y et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat. Med. 12, 441-445 (2006).
160. Chattaopadhyay S, Myers R, Janes J, Shubayev V. Cytokine regulation of MMP-9 in peripheral glia: implications for pathological processes and pain in injured nerve. Brain Behav. Immun. 21, 561-568 (2007).
161. Sheen P, O'Kane CM, Chaudhary K et al. High MMP-9 activity characterizes pleural tuberculosis correlating with granuloma formation. Eur. Respir. J. 33, 134-141 (2009). •• Provides evidence for activation of MMP-9 in tubercular pleural disease.
162. Price NM, Farrar J, Tran TT et al. Identification of a matrix-degrading phenotype in human tuberculosis in vitro and in vivo. J. Immunol. 166, 4223-4230 (2001).
163. Harris JE, Nuttall RK, Elkington PT et al. Monocyte-astrocyte networks regulate matrix metalloproteinase gene expression and secretion in central nervous system tuberculosis in vitro and in vivo. J. Immunol. 178, 1199-1207 (2007).
164. Kruit MC, van Buchem MA, Hofman PA et al. Migraine as a risk factor for subclinical brain lesions. JAMA 291, 427-434 (2004).
165. Kruit MC, Launer LJ, Ferrari MD, van Buchem MA. Brain stem and cerebellar hyperintense lesions in migraine. Stroke 37, 1109-1112 (2006).
166. Kruit MC, Launer LJ, Ferrari MD, van Buchem MA. Infarcts in the posterior circulation territory in migraine. The population-based MRI CAMERA study. Brain 128, 2068-2077 (2005).
167. Gupta V. Silent or non-clinical infarct-like lesions in the posterior circulation territory in migraine: brain hypoperfusion or hyperperfusion? Brain 129, E39 (2006).
168. Gupta VK. White matter hyperintensities: pearls and pitfalls in interpretation of MRI abnormalities. Stroke 35, 2756-2757 (2004).
169. Rozen TD. Vanishing cerebellar infarcts in a migraine patient. Cephalalgia 27, 557-560 (2007).
170. Agarwal S, Magu S, Kamal K. Reversible white matter abnormalities in a patient with migraine. Neurol. India 56, 182-185 (2008).
171. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 330, 63 (2005).
172. Steiner TJ, Joseph R, Rose FC. Migraine is not a platelet disorder. Headache 25, 434-440 (1985).
173. Bushnell CD, Jamison M, James AH. Migraines during pregnancy linked to stroke and vascular diseases: US population based case-control study. BMJ 338, B 664 (2009).
174. MacClellan LR, GilesW, Cole J et al. Probable migraine with visual aura and risk of ischemic stroke: the stroke prevention in young women study. Stroke 38, 2407-2408 (2007).
175. May A. Morphing voxels: the hype around structural imaging of headache patients. Brain 132(Pt 6), 1419-1425 (2009).
176. Parsons AA. Cortical spreading depression: its role in migraine pathogenesis and possible therapeutic intervention strategies. Curr. Pain Headache Rep. 8, 410-416 (2004).
177. Bates EA, Nikai T, Brennan KC et al. Sumatriptan alleviates nitroglycerin-induced mechanical and thermal allodynia in mice. Cephalalgia DOI 10.1111/j.1468-2982.2009.01864.x (2009) (Epub ahead of print).
178. Wolthausen J, Sternberg, Gerloff C, May A. Are cortical spreading depression and headache in migraine causally linked? Cephalalgia 29, 244-249 (2009).
179. Stankewitz A, May A. The phenomenon of changes in cortical excitability in migraine is not migraine-specific - a unifying thesis. Pain 145(1-2), 14-17 (2009).
180. Richter F, Mikulik O, Ebersberger A et al. Noradrenergic agonists and antagonists influence migration of cortical spreading depression in rat - a possible mechanism of migraine prophylaxis and prevention of postischemic neuronal damage. J. Cereb. Blood Flow Metab. 25, 1225-1235 (2005).
181. Dodick DW. Tonabersat for migraine prevention: new life or last gasp? Lancet Neurol. 8, 693-695 (2009).
182. Dodick DW. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside. Headache 43(Suppl. 1), 25-33 (2003).
183. Dowson AJ, Mullen N, Peatfield R et al. Migraine Intervention with STARFlex Technology trial: a prospective, multicentre, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation 117, 1397-1404 (2008).
184. Afridi SK, Shields KG, Bhola R, Goadsby PJ. Greater occipital nerve injection in primary headache syndromes - prolonged effects from a single injection. Pain 122, 126-129 (2006).
185. Behin F, Lipton RB, Bigal M. Migraine and intranasal contact point headache: is there any connection? Curr. Pain Headache Rep. 10 (4) 312-315 (2007).
186. Schwartz TH, Karpitskiy VV, Sohn RS. Intravenous valproate sodium in the treatment of daily headache. Headache 42(6), 519-522 (2002).
187. Robbins LD. Intravenous valproate for prolonged migraine headache. Headache 40, 427 (2000).
188. Cady RK, Mathew N, Diener HC, Hu P, Haas M, Novak GP. Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial. Headache 49(2) 216-226 (2009).
189. Silberstein S, Saper J, Berenson F, Somogyi M, McCague K, D'Souza J. Oxcarbazepine in migraine headache. A double-blind, randomized, placebo-controlled study. Neurology 70, 548-555 (2008).
190. Silberstein SD, Aoki KR. Botulinum toxin type A: myths, facts, and current research. Headache 43(Suppl. 1) 1 (2003).
191. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. Headache 40, 445-450 (2000).
192. Dodick DW, Mauskop A, Elkind AH et al.; BOTOX CDH study group. Botulinum toxin type A for the prophylaxis of chronic daily headache. Subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo- controlled study. Headache 45(4) 315-324 (2005).
193. Gupta VK. Botulinum toxin: a treatment for migraine? A systematic review. Pain Med. 7, 386-394 (2006).
194. Gupta VK. Botulinum toxin type A therapy for chronic tension-type headache: fact versus fiction. Pain 116, 166-167 (2005).
195. Schulte-Mattler WJ, Karack P, BoNTTH study group. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain 109, 110-114 (2004).
196. Schulte-Mattler WJ, Karack P. Response to Gupta VK: Botulinum toxin type A for chronic tension-type headache: fact versus fiction. Pain 116, 167 (2005).
197. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44(1) 35-42 (2004).
198. Cady R, Schreiber C. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Headache 48(6) 900-913 (2008).
199. Qerama E, Fuglsang-Frederiksen A, Kasch H, Bach FW, Jensen TS. A double-blind, controlled study of botulinum toxin A in chronic myofascial pain. Neurology 67, 241-245 (2006).
200. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type a induces direct analgesic effects in chronic neuropathic pain. Ann. Neurol. 64(3) 274-284 (2008).
201. Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 141, 60-69 (2009).
202. Gupta VK. Patent foramen ovale closure: science, quasi-science, and empiricism. Cardiology 113, 108-110 (2009).
203. Adams HP. Patent foramen ovale: paradoxical embolism and paradoxical data. Mayo Clin. Proc. 79, 15-20 (2004).
204. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP; PFO in cryptogenic stroke (PICSS) investigators. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in cryptogenic stroke study. Circulation 105, 2625-2631 (2002).
205. Berdat PA, Chatterjee T, Pfammatter JP, Windecker S, Meier B, Carrel T. Surgical management of complications after transcatheter closure of an atrial septal defect or patent foramen ovale. J. Thorac. Cardiovasc. Surg. 120, 1034-1039 (2000).
206. Humphrey PPA. The discovery and development of triptans, a major therapeutic breakthrough. Headache 48, 685-687 (2008).
207. Burstein R, Jakubowski M, Levy D. Anti-migraine action of triptans is preceded by transient aggravation of headache caused by activation of meningeal nociceptors. Pain 115, 21-28 (2005).
208. Pringsheim T, Davenport WJ, Dodick D. Acute treatment and prevention of menstrually related migraine headache. Evidence-based review. Neurology 70, 1555-1563 (2008).
209. Nikai T, Basbaum AI, Ahn AH. Profound reduction of somatic and visceral pain in mice by intrathecal administration of the anti-migraine drug, sumatriptan. Pain 139, 533-540 (2008).
210. Dowson AJ, Mathew NT, Pascual J. Review of clinical trials using early acute intervention with oral triptans for migraine management. Int. J. Clin. Pract. 60(6), 698-706 (2006).
211. Olesen J, Diener H-C, Husstedt IW et al. for the BIBN 4096 BS Clinical Proof of Concept study group. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med. 350, 1104-1110 (2004).
212. Durham PL. CGRP-receptor antagonists - a fresh approach to migraine therapy? N. Engl. J. Med. 350(11), 1073-1075 (2004).
213. Storer RJ, Akerman S, Goadsby PJ. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br. J. Pharmacol. 142, 1171-1181 (2004).
214. Ho TW, Ferrari MD, Dodick DW et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomized, placebo-controlled, parallel-treatment trial. Lancet 372(9656) 2115-2123 (2008).
215. Brain SD. Calcitonin gene-related peptide (CGRP) antagonists: blockers of neuronal transmission in migraine. Br. J. Pharmacol. 142, 1053-1054 (2004).
216. Friedman BW, Corbo J, Lipton RB et al. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology 64, 463-468 (2005).
217. Colman I, Brown MD, Innes GD, Grafstein E, Roberts TE, Rowe BH. Parenteral metoclopramide for acute migraine: meta-analysis of randomized controlled trials. BMJ 329, 1369-1373 (2004).
218. Lipton RB, Stewart WF, Stone AM, Lainez MJA, Sawyer JPC. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) study: a randomized trial. JAMA 284, 2599-2605 (2000).
219. Edmeads J. What is migraine? Controversy and stalemate in migraine pathophysiology. J. Neurol. 238, S2-S3 221 (1991).
220. van Pragg HM, Lader MH, Rafaelsen OJ, Sachar EJ. Handbook of Biological Psychiatry. Marcel Dekker, NY, USA (1979).
221. Cady RK. The future of migraine: beyond just another pill. Mayo Clin. Proc. 84(5) 397-399 (2009).
222. Feinstein AR. Clinical judgment revisited: the distraction of quantitative models. Ann. Intern. Med. 120, 799-805 (1994).
223. Herman J. Experiment and observation. Lancet 344, 1209-1211 (1994).
224. Horton RC, Kendall MJ. Clinical pharmacology and therapeutics. Postgrad. Med. J. 67, 1042-1054 (1991).
225. Hauge AW, Asghar MS, Schytz HW, Christensen K, Olesen J. Effects of tonerbasat on migraine with aura: a randomized, double-blind, placebo-controlled crossover study. Lancet Neurol. 8(8), 718-723 (2009).
226. Marincola FM. In support of descriptive studies: relevance to translational research. J. Transl. Med. 5, 21 (2007).
227. Gupta VK. Migraine and unilateral giveway motor weakness: atypical, pseudo-paretic behavioural epiphenomenon. J. Neurol. Neurosug. Psychiatry (2006) http://jnnp.bmjjournals.com/cgi/eletters/jnnp.2006.100214v1#1160
228. Gupta VK. Classification of primary headaches: pathophysiology versus nosology? Br. Med. J. (2004) http://bmj.bmjjournals.com/cgi/eletters/328/7432/ 119